Gammadelta T cells represent a unique subset of T cells that bridge innate and adaptive immunity by recognizing self and foreign nonpeptide antigens. In addition to their role in microbial immunity, there is strong evidence that human gammadelta T cells help regulate B cell malignancies such as non-Hodgkin's lymphoma (NHL) and multiple myeloma. Supporting this hypothesis, gammadelta? T cells expand in some patients with lymphoid malignancies to up to 42% of circulating T cells. Human Vgamma2Vdelta2 T cells recognize and kill a subset of NHLs and multiple myelomas. Vgamma2Vdelta2 T cells can provide immunity for NHL in a SCID mouse model. Moreover, immunotherapy of lymphoma patients with synthetic bisphosphonate antigens and IL-2 to stimulate Vgamma2Vdelta2 T cells shows promise since it resulted in partial remissions or stable disease in 4 of 5 patients that had Vgamma2Vdelta2 T cell proliferation. For this immunotherapy to be more effective, basic knowledge is needed about how Vgamma2Vdelta2 T cells respond to nonpeptide antigens, how gammadelta T cell memory develops, and what are the most effective ways to stimulate Vgamma2Vdelta2 T cells in vivo. We have found that adult Vgamma2Vdelta2 T cells are almost exclusively memory cells that are divided into 3 subsets, central memory, effector memory, and effector CD45RA+memory. Each subset has distinctive functional and migratory properties. We find that central memory Vgamma2Vdelta2 T cells are deleted or anergized in multiple myeloma patients that have been treated with the bisphosphonate, zolendronate, in the absence of rIL-2. Here we propose to test the hypothesis that Vgamma2Vdelta2 T cells recognize and kill a subset of malignant B cells that have elevated levels of IPP and NKG2D ligands. Activating V?2V?2 T cells with nonpeptide antigens and growth factors can lead to the elimination or stabilization of disease in patients with B cell malignancies.
In Aim 1, we will correlate expression of NKG2D ligands with the ability of malignant B cells to stimulate Vgamma2Vdelta2 T cells.
In Aim 2, we will test different memory subsets of Vgamma2Vdelta2 T cells for their ability to control lymphomas in adaptive immunotherapy in an in vivo SCID-beige mouse model.
In Aim 3, we will test vaccination protocols using bisphosphonate antigens, adjuvants, and growth cytokines in monkeys for their ability to stimulate Vgamma2Vdelta2 T cells. These studies will help to elucidate the molecular basis of Vgamma2Vdelta2T cell recognition of malignant B cells and the function of memory gammadelta T cell subsets in lymphoma immunity and will provide crucial information on optimising immunotherapy with gammadelta T cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA113874-01
Application #
6906987
Study Section
Transplantation, Tolerance, and Tumor Immunology (TTT)
Program Officer
Howcroft, Thomas K
Project Start
2005-09-01
Project End
2009-06-30
Budget Start
2005-09-01
Budget End
2006-06-30
Support Year
1
Fiscal Year
2005
Total Cost
$233,050
Indirect Cost
Name
University of Iowa
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Sugie, Tomoharu; Murata-Hirai, Kaoru; Iwasaki, Masashi et al. (2013) Zoledronic acid-induced expansion of ?? T cells from early-stage breast cancer patients: effect of IL-18 on helper NK cells. Cancer Immunol Immunother 62:677-87
Idrees, Atif S M; Sugie, Tomoharu; Inoue, Chiyomi et al. (2013) Comparison of ?? T cell responses and farnesyl diphosphate synthase inhibition in tumor cells pretreated with zoledronic acid. Cancer Sci 104:536-42
Giner, José-Luis; Wang, Hong; Morita, Craig T (2012) Synthesis and immunological evaluation of the 4-?-glucoside of HMBPP. Bioorg Med Chem Lett 22:811-3
Wang, Hong; Sarikonda, Ghanashyam; Puan, Kia-Joo et al. (2011) Indirect stimulation of human V?2V?2 T cells through alterations in isoprenoid metabolism. J Immunol 187:5099-113
Ness-Schwickerath, Kristin J; Jin, Chenggang; Morita, Craig T (2010) Cytokine requirements for the differentiation and expansion of IL-17A- and IL-22-producing human Vgamma2Vdelta2 T cells. J Immunol 184:7268-80
Gutzeit, Cindy; Raftery, Martin J; Peiser, Matthias et al. (2010) Identification of an important immunological difference between virulent varicella-zoster virus and its avirulent vaccine: viral disruption of dendritic cell instruction. J Immunol 185:488-97
Zhang, Yonghui; Cao, Rong; Yin, Fenglin et al. (2010) Lipophilic pyridinium bisphosphonates: potent gammadelta T cell stimulators. Angew Chem Int Ed Engl 49:1136-8
Wang, Hong; Fang, Zhimei; Morita, Craig T (2010) Vgamma2Vdelta2 T Cell Receptor recognition of prenyl pyrophosphates is dependent on all CDRs. J Immunol 184:6209-22
Puan, Kia Joo; Low, John Seng Hooi; Tan, Terence Wee Kiat et al. (2009) Phenotypic and functional alterations of Vgamma2Vdelta2 T cell subsets in patients with active nasopharyngeal carcinoma. Cancer Immunol Immunother 58:1095-107
Song, Yongcheng; Lin, Fu-Yang; Yin, Fenglin et al. (2009) Phosphonosulfonates are potent, selective inhibitors of dehydrosqualene synthase and staphyloxanthin biosynthesis in Staphylococcus aureus. J Med Chem 52:976-88

Showing the most recent 10 out of 12 publications